Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.

Zouhair Souissi

Bibliographie

18 mai 2021

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy – EClinicalMedicine

The post SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. appeared first on Links Medicus.

Lu 692 fois

Taille de police Réduire la taille de la police Augmenter la taille de police

Évaluer cet élément

1
2
3
4
5

(0 Votes)

Plus dans cette catégorie : « COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”. M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively. »

About Author

Zouhair Souissi

Dernier de Zouhair Souissi

Recherche